Get Project Twenty21 Updates via Email Project Twenty21: August Update 16th August 2022 We’re doing some work behind the scenes to revamp the way our monthly T21 data update is laid out, so this month’s data points will be a little delayed and released as soon as they are ready – please bear with us! In the meantime, …
The Psychedelic Access and Research European Alliance (PAREA) has officially launched with an impressive array of wide-ranging support amongst charities, patient groups, not-for-profits and psychedelic industry partners. Drug Science was an incubator for the PAREA collective. We recognised that to ensure that psychedelic-assisted psychotherapy was integrated into each EU member state’s healthcare system, a centralised …
By Professor David Nutt and James Bunn The Drug Enforcement Agency (DEA) recently withdrew a proposal to ban five psychedelic substances: 4-Hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alphamethyltryptamine (5-MeO-AMT), N-Isopropyl-5-Methoxy-N-Methyltryptamine (5-MeO-MiPT), N,N-Diethyl-5-methoxytryptamine (5-MeO-DET), and N,N-Diisopropyltryptamine (DiPT). Earlier this year, the DEA proposed that these substances ought to be moved to schedule 1 (the most restrictive schedule in the Controlled …
What is the Special Access Programme? On January 5th 2022, Health Canada amended the Food and Drug Regulations and the Narcotic Control Regulations to allow previously excluded ‘psychedelic’ drugs such as Psilocybin to be included on the ‘Special Access Programme’ (SAP). The SAP allows healthcare practitioners to request limited access to drugs that are not …
Author Petter Grahl Johnstad Published July 25, 2022 Abstract Researchers have associated cannabis use with risk for psychosis, cognitive impairment, and traffic accident. However, this review shows that the association between moderate cannabis use and psychosis is no stronger, and often considerably weaker, than the corresponding association for moderate tobacco use. The same holds for …
On the 30th of October 2019, our Founder – Professor David Nutt spoke at the Centre for Crime and Justice Studies with Professor Alex Stevens about the regression of drug policy in the UK. This was later reported in the British Medical Journal as follows: Drug policy in UK has regressed in past decade, says …
Job brief We are looking for a Communications Director to join our core team. We are in an exciting stage of growth as an organisation, one that will reward initiative and a growth mindset with opportunities for fast career development. We are looking for a talented communicator who thrives off translating the scientific evidence-base for …
Today (13th August 2019), the independent scientific body Drug Science has responded with disappointment to a decision by the National Institute for Health and Care Excellence (NICE), relating to cannabis-related medical products. In November 2018, the then Home Secretary Sajid Javid introduced regulations so that cannabis-derived medicinal products would be available on prescription. This change …
Drug Science is delighted to support The Cannabis Society Medical Conference, being held on 24th June in Central London. The Cannabis Society is dedicated to fostering the cannabis community through events, conferences, dinners and much more. The conference is an opportunity to join with doctors from both Europe and North America, industry experts, investors and …
Please download the conference background materials here, including: Meeting slides DrugScience report on medicinal cannabis DrugScience cannabis pre-review submitted to the WHO Expert Committee on Drug Dependence Summaries of international and American medicinal cannabis licensing The Chief Medical Officer and advisor to the UK government has recently agreed that cannabis is a medicine. It has …
By Professor David Nutt and James Bunn The Drug Enforcement Agency (DEA) recently withdrew a proposal to ban five psychedelic substances: 4-Hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alphamethyltryptamine (5-MeO-AMT), N-Isopropyl-5-Methoxy-N-Methyltryptamine (5-MeO-MiPT), N,N-Diethyl-5-methoxytryptamine (5-MeO-DET), and N,N-Diisopropyltryptamine (DiPT). Earlier this year, the DEA proposed that these substances ought to be moved to schedule 1 (the most restrictive schedule in the Controlled …
In 2019, Drug Science submitted evidence to the Drugs Policy Inquiry by the Health and Social Care Committee. In 2020, we prepared a detailed report in response to the Dame Carol Black Drugs Review. In 2021, we reacted to the government’s 10-year Drug Strategy. Our 2022 response to the UK government’s call for evidence of …
Mephedrone is the common name for 4-methylmethcathinone. This is a synthetic derivative of cathinone, first synthesized in 1929, and largely forgotten until the early 2000s when Israeli scientists working for an insecticide company started experimenting with cathinones as octopamine analogues to disrupt the brain activity of aphids so make them less damaging to plants. Mephedrone …
By Dr. Shanna Marrinan Since the 2nd of March 2015, it has been illegal to drive with predetermined amounts of particular drugs (including legal medications) in your blood. The limits for these legal and illegal drugs can be located in ‘The Drug Driving (Specified Limits) (England and Wales) Regulations 2014’ (hereafter the 2014 regulations’). However, a handy …
Foreword by Professor David Nutt Lies, damn lies and vaping statistics- To paraphrase Disraeli’s famous critique of statistics the so-called science of vaping now seems to have become even worse than dishonest. In the past 6 months we have seen across the world a deliberate attempt to mislead the public over the harms of vaping …
